Clinical Trials Browser

Completed × Has results × isatuximab × Clear all

Multiple Myeloma

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 3 FDA

Plasma cell

Multiple Myeloma

NCT01084252 2024-11-01

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Phase 1/2 Completed

351 enrolled 56 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Plasma cell

Multiple Myeloma

NCT02812706 2024-04-01

Islands

Phase 1/2 Completed

36 enrolled 26 charts

Plasma cell

Multiple Myeloma

Clinical Trials

IKEMA

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

ICARIA-MM

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Islands